GeneCode (EE)

https://www.genecode.com

GENECODE LTD was founded in 1993 in Tallinn, Estonia. GENECODE is a private Estonian-American-Finnish-Dutch R&D company, developing innovative treatment strategies in neurodegenerative diseases and anti-virals. For neurodegenerative diseases, GeneCode applies proprietary drug design technologies for innovative target mechanisms. This enables the synthesis and development of novel small-molecule drug candidates which validates the target biology towards its proposed indications, such as Parkinson`s disease, spinal cord injury, Huntington’s disease, motor neuronal disease, multiple sclerosis, Alzheimer’s disease and pain. The overall ambition is to develope neuroprotective and potentially neurorestorative treatment which is –as yet – unavailable. With respect to anti-viral strategies, GeneCode designed and develops improved molecules using antisense mechanism of action which targets viral genomes and transcripts. By disrupting the viral lifecycle GeneCode’s approach is delivering promising treatment options for Hepatitis C, HIV and Chikungunya virus. All proprietary methods for novel drug design technologies and drug candidates developed by GeneCode are aimed to function as disease modifyers and ultimately as cures, not as disease symptom treatments. Both the identification and optimization of small molecule methods towards growth factor receptors and the antisense technologies have been globally patented and serve GeneCode’s new Technological Platforms of drug design. *

	Start	1993-01-01 established
	Industry	BIOTECH
	Industry 2	GDNF mimetic (small molecule Glial cell line-Derived Neurotrophic Factor mimetic)
	Person	Pily, Paavo (GeneCode 202112 CEO)

	City	n. a. Tallinn
		Address record changed: 2021-12-19

Basic data	Employees	n. a.

		�About Section� taken from web site of organisation on 17.12.

		Record changed: 2025-03-16

Picture Informa Connect BioProcess Intl Europe 2025 Hamburg Register 650x200px

More documents for GeneCode (EE)

[1] Argobio SAS. (12/16/21). "Press Release: Argobio and GeneCode Partner on Parkinson’s Disease in Argobio’s First Announced Research Agreement". Paris & Tallinn....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)